Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property
Authors:
Open Access
- 26 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Long term benefits following short-term administration of high psychedelic doses of serotonergic and dissociative hallucinogens, typified by psilocybin and ketamine respectively, support their potential as treatments for psychiatric conditions such as major depressive disorder. The high psychedelic doses induce perceptual experiences which are associated with therapeutic benefit. There have also been anecdotal reports of these drugs being used at what are colloquially referred to as “micro” doses to improve mood and cognitive function, although currently there are recognized limitations to their clinical and preclinical investigation. In the present studies we have defined a low dose and plasma exposure range in rats for both ketamine (0.3–3 mg/kg [10–73 ng/ml]) and psilocybin/psilocin (0.05–0.1 mg/kg [7–12 ng/ml]), based on studies which identified these as sub-threshold for the induction of behavioral stereotypies. Tests of efficacy were focused on depression-related endophenotypes of anhedonia, amotivation and cognitive dysfunction using low performing male Long Evans rats trained in two food motivated tasks: a progressive ratio (PR) and serial 5-choice (5-CSRT) task. Both acute doses of ketamine (1–3 mg/kg IP) and psilocybin (0.05–0.1 mg/kg SC) pretreatment increased break point for food (PR task), and improved attentional accuracy and a measure of impulsive action (5-CSRT task). In each case, effect size was modest and largely restricted to test subjects characterized as “low performing”. Furthermore, both drugs showed a similar pattern of effect across both tests. The present studies provide a framework for the future study of ketamine and psilocybin at low doses and plasma exposures, and help to establish the use of these lower concentrations of serotonergic and dissociative hallucinogens both as a valid scientific construct, and as having a therapeutic utility.Keywords
This publication has 103 references indexed in Scilit:
- Highly impulsive rats: modelling an endophenotype to determine the neurobiological, genetic and environmental mechanisms of addictionDisease Models & Mechanisms, 2013
- Data-driven subtypes of major depressive disorder: a systematic reviewBMC Medicine, 2012
- Dopaminergic Modulation of Effort-Related Choice Behavior as Assessed by a Progressive Ratio Chow Feeding Choice Task: Pharmacological Studies and the Role of Individual DifferencesPLOS ONE, 2012
- Targeting the Glutamatergic System to Treat Major Depressive DisorderDrugs, 2012
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinProceedings of the National Academy of Sciences, 2012
- Impulsivity and Rapid Decision-Making for RewardFrontiers in Psychology, 2012
- Reconsidering anhedonia in depression: Lessons from translational neuroscienceNeuroscience & Biobehavioral Reviews, 2011
- Glutamate Receptor Ion Channels: Structure, Regulation, and FunctionPharmacological Reviews, 2010
- Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal ModelsNeuropsychopharmacology, 2008
- Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmissionPharmacology & Therapeutics, 2007